Delphi Genetics SA announced today the closing of a capital increase in excess of 1 Million EUR
Delphi Genetics SA announced today the closing of a capital increase in excess of 1 Million EUR to support its latest development in “Good Manufacturing Practices (GMP)” services for protein and DNA productions, especially engineered for small/medium scale needs. Equity funds were provided by lead investors Sambrinvest (a venture capital fund active in Charleroi/Thuin area) and Invest4 DelphiG2 (Mr. François Blondel and Dr. Philippe Janssens de Varebeke), together with the two managing directors of the company, Mr. Michel Milinkovitch and ULB (Université Libre de Bruxelles) through its fund Theodorus SCA. David De Permentier, Managing Director, commented: “These funds will enable Delphi Genetics to accelerate its internal research developments whilst continuing to offer a unique expertise and technology to support our valuable customers”. And Cédric Szpirer PhD, Founder and Executive & Scientific Director, further added that “after more than 10 years of activity, it is an important step in the development of Delphi Genetics: the broadening of the investor base is an indication of their confidence in our Staby® technologies for biomolecule productions (DNA and proteins) and antibody development”.